Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck : A phase II Southwest Oncology Group study

Twenty-nine patients with persistent, recurrent and/or metastatic squamous cell carcinoma of the head and neck were treated daily for five days at three-week intervals with topotecan 1.5 mg/m2. Four patients received prior chemotherapy, 23 prior surgery and 29 prior radiation therapy. Of the 29 elig...

Full description

Saved in:
Bibliographic Details
Published in:Investigational new drugs 1996-01, Vol.14 (4), p.403-407
Main Authors: SMITH, R. E, LEW, D, RODRIGUEZ, G. I, TAYLOR, S. A, SCHULLER, D, ENSLEY, J. F
Format: Article
Language:English
Subjects:
Adult
Aged
Aged, 80 and over
Antineoplastic agents
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Camptothecin - adverse effects
Camptothecin - analogs & derivatives
Camptothecin - therapeutic use
Carcinoma, Squamous Cell - drug therapy
Chemotherapy
Drug Administration Schedule
Female
Head and Neck Neoplasms - drug therapy
Humans
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Topotecan
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by
cites cdi_FETCH-LOGICAL-c270t-242c440273938bb9907cb36822cda9d22853286493395fc07c69f528a0e49bd63
container_end_page 407
container_issue 4
container_start_page 403
container_title Investigational new drugs
container_volume 14
creator SMITH, R. E
LEW, D
RODRIGUEZ, G. I
TAYLOR, S. A
SCHULLER, D
ENSLEY, J. F
description Twenty-nine patients with persistent, recurrent and/or metastatic squamous cell carcinoma of the head and neck were treated daily for five days at three-week intervals with topotecan 1.5 mg/m2. Four patients received prior chemotherapy, 23 prior surgery and 29 prior radiation therapy. Of the 29 eligible patients, 8 patients were not evaluable for response and were assumed to be non-responders. Of the remaining 21 evaluable patients, there were zero responses (0%, 95% confidence interval [0,.12]). The most common toxicities were myelosuppression, dyspnea and malaise/fatigue/lethargy. Topotecan has limited activity in advanced head and neck cancer with this dose and schedule.
doi_str_mv 10.1007/BF00180818
format article
fullrecord <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_crossref_primary_10_1007_BF00180818</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>9157077</sourcerecordid><originalsourceid>FETCH-LOGICAL-c270t-242c440273938bb9907cb36822cda9d22853286493395fc07c69f528a0e49bd63</originalsourceid><addsrcrecordid>eNpFkMFO3DAQhq2qiC4Ll94rzaGnSikTOxvH3Ba0S1dC4gCcVxPHaQKJHWynq32VPm1TWC2n0cz36dfoZ-xrij9TRHl5vUZMCyzS4hObpQspEsyz_DObYZrLJFdKfmFnITwjolAyO2WnarJQyhn7u_pD3UixdRZcDdENLhpNFloLw3Q2NgbYtbEBb_To_bRD7Tz0JlKIk6AhvI7UuzGANl0HmrxurevpLa4x0BiqgGwF1ugXuIIlDA0FA5sNPLgxNjsTItxb7Tr3ew-33o0DhDhW-3N2UlMXzMVhztnTevV48yu5u7_d3CzvEs0lxoRnXGcZcimUKMpSKZS6FHnBua5IVZwXC8GLPFNCqEWtJ5qresELQpOpssrFnP14z9XeheBNvR1825Pfb1Pc_u93-9HvJH97l4ex7E11VA-FTvz7gVPQ1NWerG7DUeNy-pMr8Q9WtoMF</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck : A phase II Southwest Oncology Group study</title><source>Springer LINK Archives</source><creator>SMITH, R. E ; LEW, D ; RODRIGUEZ, G. I ; TAYLOR, S. A ; SCHULLER, D ; ENSLEY, J. F</creator><creatorcontrib>SMITH, R. E ; LEW, D ; RODRIGUEZ, G. I ; TAYLOR, S. A ; SCHULLER, D ; ENSLEY, J. F</creatorcontrib><description>Twenty-nine patients with persistent, recurrent and/or metastatic squamous cell carcinoma of the head and neck were treated daily for five days at three-week intervals with topotecan 1.5 mg/m2. Four patients received prior chemotherapy, 23 prior surgery and 29 prior radiation therapy. Of the 29 eligible patients, 8 patients were not evaluable for response and were assumed to be non-responders. Of the remaining 21 evaluable patients, there were zero responses (0%, 95% confidence interval [0,.12]). The most common toxicities were myelosuppression, dyspnea and malaise/fatigue/lethargy. Topotecan has limited activity in advanced head and neck cancer with this dose and schedule.</description><identifier>ISSN: 0167-6997</identifier><identifier>EISSN: 1573-0646</identifier><identifier>DOI: 10.1007/BF00180818</identifier><identifier>PMID: 9157077</identifier><identifier>CODEN: INNDDK</identifier><language>eng</language><publisher>Dordrecht: Kluwer</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Antineoplastic agents ; Antineoplastic Agents - adverse effects ; Antineoplastic Agents - therapeutic use ; Biological and medical sciences ; Camptothecin - adverse effects ; Camptothecin - analogs &amp; derivatives ; Camptothecin - therapeutic use ; Carcinoma, Squamous Cell - drug therapy ; Chemotherapy ; Drug Administration Schedule ; Female ; Head and Neck Neoplasms - drug therapy ; Humans ; Male ; Medical sciences ; Middle Aged ; Pharmacology. Drug treatments ; Topotecan</subject><ispartof>Investigational new drugs, 1996-01, Vol.14 (4), p.403-407</ispartof><rights>1997 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c270t-242c440273938bb9907cb36822cda9d22853286493395fc07c69f528a0e49bd63</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=2727329$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/9157077$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>SMITH, R. E</creatorcontrib><creatorcontrib>LEW, D</creatorcontrib><creatorcontrib>RODRIGUEZ, G. I</creatorcontrib><creatorcontrib>TAYLOR, S. A</creatorcontrib><creatorcontrib>SCHULLER, D</creatorcontrib><creatorcontrib>ENSLEY, J. F</creatorcontrib><title>Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck : A phase II Southwest Oncology Group study</title><title>Investigational new drugs</title><addtitle>Invest New Drugs</addtitle><description>Twenty-nine patients with persistent, recurrent and/or metastatic squamous cell carcinoma of the head and neck were treated daily for five days at three-week intervals with topotecan 1.5 mg/m2. Four patients received prior chemotherapy, 23 prior surgery and 29 prior radiation therapy. Of the 29 eligible patients, 8 patients were not evaluable for response and were assumed to be non-responders. Of the remaining 21 evaluable patients, there were zero responses (0%, 95% confidence interval [0,.12]). The most common toxicities were myelosuppression, dyspnea and malaise/fatigue/lethargy. Topotecan has limited activity in advanced head and neck cancer with this dose and schedule.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Antineoplastic agents</subject><subject>Antineoplastic Agents - adverse effects</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Camptothecin - adverse effects</subject><subject>Camptothecin - analogs &amp; derivatives</subject><subject>Camptothecin - therapeutic use</subject><subject>Carcinoma, Squamous Cell - drug therapy</subject><subject>Chemotherapy</subject><subject>Drug Administration Schedule</subject><subject>Female</subject><subject>Head and Neck Neoplasms - drug therapy</subject><subject>Humans</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Pharmacology. Drug treatments</subject><subject>Topotecan</subject><issn>0167-6997</issn><issn>1573-0646</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1996</creationdate><recordtype>article</recordtype><recordid>eNpFkMFO3DAQhq2qiC4Ll94rzaGnSikTOxvH3Ba0S1dC4gCcVxPHaQKJHWynq32VPm1TWC2n0cz36dfoZ-xrij9TRHl5vUZMCyzS4hObpQspEsyz_DObYZrLJFdKfmFnITwjolAyO2WnarJQyhn7u_pD3UixdRZcDdENLhpNFloLw3Q2NgbYtbEBb_To_bRD7Tz0JlKIk6AhvI7UuzGANl0HmrxurevpLa4x0BiqgGwF1ugXuIIlDA0FA5sNPLgxNjsTItxb7Tr3ew-33o0DhDhW-3N2UlMXzMVhztnTevV48yu5u7_d3CzvEs0lxoRnXGcZcimUKMpSKZS6FHnBua5IVZwXC8GLPFNCqEWtJ5qresELQpOpssrFnP14z9XeheBNvR1825Pfb1Pc_u93-9HvJH97l4ex7E11VA-FTvz7gVPQ1NWerG7DUeNy-pMr8Q9WtoMF</recordid><startdate>19960101</startdate><enddate>19960101</enddate><creator>SMITH, R. E</creator><creator>LEW, D</creator><creator>RODRIGUEZ, G. I</creator><creator>TAYLOR, S. A</creator><creator>SCHULLER, D</creator><creator>ENSLEY, J. F</creator><general>Kluwer</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope></search><sort><creationdate>19960101</creationdate><title>Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck : A phase II Southwest Oncology Group study</title><author>SMITH, R. E ; LEW, D ; RODRIGUEZ, G. I ; TAYLOR, S. A ; SCHULLER, D ; ENSLEY, J. F</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c270t-242c440273938bb9907cb36822cda9d22853286493395fc07c69f528a0e49bd63</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1996</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Antineoplastic agents</topic><topic>Antineoplastic Agents - adverse effects</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Camptothecin - adverse effects</topic><topic>Camptothecin - analogs &amp; derivatives</topic><topic>Camptothecin - therapeutic use</topic><topic>Carcinoma, Squamous Cell - drug therapy</topic><topic>Chemotherapy</topic><topic>Drug Administration Schedule</topic><topic>Female</topic><topic>Head and Neck Neoplasms - drug therapy</topic><topic>Humans</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Pharmacology. Drug treatments</topic><topic>Topotecan</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>SMITH, R. E</creatorcontrib><creatorcontrib>LEW, D</creatorcontrib><creatorcontrib>RODRIGUEZ, G. I</creatorcontrib><creatorcontrib>TAYLOR, S. A</creatorcontrib><creatorcontrib>SCHULLER, D</creatorcontrib><creatorcontrib>ENSLEY, J. F</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><jtitle>Investigational new drugs</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>SMITH, R. E</au><au>LEW, D</au><au>RODRIGUEZ, G. I</au><au>TAYLOR, S. A</au><au>SCHULLER, D</au><au>ENSLEY, J. F</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck : A phase II Southwest Oncology Group study</atitle><jtitle>Investigational new drugs</jtitle><addtitle>Invest New Drugs</addtitle><date>1996-01-01</date><risdate>1996</risdate><volume>14</volume><issue>4</issue><spage>403</spage><epage>407</epage><pages>403-407</pages><issn>0167-6997</issn><eissn>1573-0646</eissn><coden>INNDDK</coden><abstract>Twenty-nine patients with persistent, recurrent and/or metastatic squamous cell carcinoma of the head and neck were treated daily for five days at three-week intervals with topotecan 1.5 mg/m2. Four patients received prior chemotherapy, 23 prior surgery and 29 prior radiation therapy. Of the 29 eligible patients, 8 patients were not evaluable for response and were assumed to be non-responders. Of the remaining 21 evaluable patients, there were zero responses (0%, 95% confidence interval [0,.12]). The most common toxicities were myelosuppression, dyspnea and malaise/fatigue/lethargy. Topotecan has limited activity in advanced head and neck cancer with this dose and schedule.</abstract><cop>Dordrecht</cop><pub>Kluwer</pub><pmid>9157077</pmid><doi>10.1007/BF00180818</doi><tpages>5</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0167-6997
ispartof Investigational new drugs, 1996-01, Vol.14 (4), p.403-407
issn 0167-6997
1573-0646
language eng
recordid cdi_crossref_primary_10_1007_BF00180818
source Springer LINK Archives
subjects Adult
Aged
Aged, 80 and over
Antineoplastic agents
Antineoplastic Agents - adverse effects
Antineoplastic Agents - therapeutic use
Biological and medical sciences
Camptothecin - adverse effects
Camptothecin - analogs & derivatives
Camptothecin - therapeutic use
Carcinoma, Squamous Cell - drug therapy
Chemotherapy
Drug Administration Schedule
Female
Head and Neck Neoplasms - drug therapy
Humans
Male
Medical sciences
Middle Aged
Pharmacology. Drug treatments
Topotecan
title Evaluation of topotecan in patients with recurrent for metastatic squamous cell carcinoma of the head and neck : A phase II Southwest Oncology Group study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T14%3A07%3A32IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Evaluation%20of%20topotecan%20in%20patients%20with%20recurrent%20for%20metastatic%20squamous%20cell%20carcinoma%20of%20the%20head%20and%20neck%20:%20A%20phase%20II%20Southwest%20Oncology%20Group%20study&rft.jtitle=Investigational%20new%20drugs&rft.au=SMITH,%20R.%20E&rft.date=1996-01-01&rft.volume=14&rft.issue=4&rft.spage=403&rft.epage=407&rft.pages=403-407&rft.issn=0167-6997&rft.eissn=1573-0646&rft.coden=INNDDK&rft_id=info:doi/10.1007/BF00180818&rft_dat=%3Cpubmed_cross%3E9157077%3C/pubmed_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c270t-242c440273938bb9907cb36822cda9d22853286493395fc07c69f528a0e49bd63%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_id=info:pmid/9157077&rfr_iscdi=true